At the pulse of heart disease

We are pioneers in the discovery and development of non-coding RNA-based therapeutics designed to address the root causes of heart disease.

We leverage our deep RNA biology expertise to enable a paradigm shift in the treatment of heart disease

Our Approach

We strive every day to push the boundaries and explore new frontiers in heart disease treatment

Our Core

Because your heart matters

We are advancing transformative treatments to change the lives of millions of patients with different heart diseases

Clinical Trials

Download the Cardior Factsheet

Cardior is officially funded by

Europäischer Sozialfonds und Europa für Niedersachsen

News

All News

Cardior Welcomes Dr. Orly Vardeny as Permanent Guest to the Board

Hanover, Germany, December 1, 2022 – Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced that Orly Vardeny, PharmD, MS, joins its Board of Directors as a permanent guest.

Press Release · December 1, 2022

Cardior opens new headquarter thum althusmann ulbrich

Cardior opens new headquarter in official ribbon cutting ceremony with Dr. Bernd Althusmann, Deputy Prime Minister of Lower Saxony and Minister of Economic Affairs, Labour, Transportation and Digitization

On September 14, 2022, we have officially opened our new headquarters in Hollerithallee 20, 30419 Hanover. Our scientific roots have always been in the Hanover region and we look forward to continuing our international growth from our new headquarters, demonstrating the scientific excellence and entrepreneurial spirit we have experienced in this city.

Cardior News · September 14, 2022

View impressions Watch video

All News